$-0.82 EPS Expected for Heron Therapeutics, Inc. (HRTX); First Bancorp Has 1.41 Sentiment

April 21, 2018 - By Henry Gaston

The First Bancorp, Inc. (NASDAQ:FNLC) Logo

Analysts expect Heron Therapeutics, Inc. (NASDAQ:HRTX) to report $-0.82 EPS on May, 9.They anticipate $0.18 EPS change or 18.00% from last quarter’s $-1 EPS. After having $-1.09 EPS previously, Heron Therapeutics, Inc.’s analysts see -24.77% EPS growth. The stock increased 4.36% or $1.3 during the last trading session, reaching $31.15. About 1.01 million shares traded. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 87.03% since April 21, 2017 and is uptrending. It has outperformed by 75.48% the S&P500.

First Bancorp Inc (FNLC) investors sentiment increased to 1.41 in 2017 Q4. It’s up 0.63, from 0.78 in 2017Q3. The ratio is better, as 24 investment managers increased or opened new holdings, while 17 trimmed and sold stock positions in First Bancorp Inc. The investment managers in our database now hold: 3.37 million shares, up from 3.35 million shares in 2017Q3. Also, the number of investment managers holding First Bancorp Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 14 Increased: 18 New Position: 6.

The First Bancorp, Inc. operates as the holding firm for First National Bank that provides a range of banking services and products to individual and corporate clients in coastal and eastern Maine. The company has market cap of $309.67 million. The firm offers various deposit products, such as demand, checking, NOW, saving, money market, and certificates of deposit accounts. It has a 15.77 P/E ratio. It also provides loan products, including commercial real estate, commercial construction, and other commercial loans; municipal loans for capitalized expenditures, construction projects, or tax-anticipation notes; residential term loans comprising amortizing home mortgages and construction loans, which include loans for owner-occupied residential construction; home equity loans and lines of credit; and consumer loans, which are amortizing loans to individuals collateralized by automobiles, pleasure crafts, and recreation vehicles, as well as unsecured short-term time notes.

Since January 1, 0001, it had 1 insider buy, and 0 insider sales for $29,848 activity.

The stock increased 1.78% or $0.5 during the last trading session, reaching $28.55. About 7,858 shares traded. The First Bancorp, Inc. (FNLC) has risen 4.26% since April 21, 2017 and is uptrending. It has underperformed by 7.29% the S&P500.

Qcm Cayman Ltd. holds 0.33% of its portfolio in The First Bancorp, Inc. for 15,754 shares. Naples Global Advisors Llc owns 34,665 shares or 0.28% of their US portfolio. Moreover, Hamel Associates Inc. has 0.19% invested in the company for 14,575 shares. The Maine-based Portland Global Advisors Llc has invested 0.14% in the stock. Foundry Partners Llc, a Minnesota-based fund reported 110,920 shares.

Among 15 analysts covering Heron Therapeutics (NASDAQ:HRTX), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 42 analyst reports since August 3, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Buy” rating and $31.0 target in Friday, January 5 report. Oppenheimer maintained it with “Buy” rating and $3400 target in Tuesday, March 27 report. The rating was initiated by Lake Street with “Buy” on Thursday, December 10. The rating was maintained by Mizuho on Tuesday, November 7 with “Buy”. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, January 31. Cowen & Co maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) rating on Wednesday, December 6. Cowen & Co has “Buy” rating and $40.0 target. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, February 27. Oppenheimer maintained the shares of HRTX in report on Monday, March 19 with “Buy” rating. Jefferies maintained the shares of HRTX in report on Monday, June 12 with “Buy” rating. Jefferies maintained the stock with “Buy” rating in Wednesday, September 23 report.

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company has market cap of $2.20 billion. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection. It currently has negative earnings. It offers SUSTOL extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens.

The First Bancorp, Inc. (NASDAQ:FNLC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.